Get started
Author

Rubén Fernández

Observed names: R. Fernández, Ruben Fernandez, Ruben Fernández
ORCID: 0000-0003-1325-896X
Observed ORCID: 0000-0003-1325-896X
OpenAlex ID: A5102953340
Validation of the NCCN ‐ IPI for diffuse large B‐cell lymphoma ( DLBCL ): the addition of β2‐microglobulin yields a more accurate GELTAMO ‐ IPI
2017 · Carlos Montalbán, Antonio Díaz‐López, et al. · British Journal of Haematology · 83
PDF
Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma
2019 · Elena Mata, Sara Fernández, et al. · Blood Cancer Journal · 32
PDF
On the prediction of Hodgkin lymphoma treatment response
2015 · E. J. deAndrés-Galiana, J. L. Fernández-Martínez, et al. · Clinical & Translational Oncology · 25
Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma
2019 · Rubén Pampín, Yoar Labeaga, et al. · Journal of Oncology Pharmacy Practice · 14
Differential prognostic impact of GELTAMO ‐ IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm
2018 · Carlos Montalbán, Antonio Díaz‐López, et al. · British Journal of Haematology · 9
PDF
Lymphomatoid Granulomatosis of Central Nervous System and Lung Driven by Epstein Barr Virus Proliferation: Successful Treatment with Rituximab
2014 · Ruben Fernandez, Esther Gonzalez, et al. · Mediterranean Journal of Hematology and Infectious Diseases · 8
PDF
Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO
2025 · Antonio Gutierrez, Izaskun Zeberio, et al. · Blood Advances · 7
PDF
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study
2021 · Patricia Baltasar, María José Terol, et al. · Blood · 3
Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
2019 · Antonio Gutierrez, Leyre Bento, et al. · European Journal Of Haematology · 3
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
2022 · Christelle Ferra, María José Terol, et al. · Blood · 2
Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients
2021 · Matthew R Wilson, Toby A. Eyre, et al. · Blood · 2
Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in routine clinical practice in Spain
2025 · Raul Cordoba, María Dolores García, et al. · Blood · 1
PDF
Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy
2019 · C Jiménez Cortegana, N Palazón Carrión, et al. · Annals of Oncology · 1
Outcome of first-line therapy in patients with systemic light-chain amyloidosis: A multicentre analysis
2019 · Rubén Fernández, Ana Silva - Soto, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Evaluation of Bone Marrow Infiltration by Multidimensional Flow Cytometry in Patients With Diffuse Large B‐cell Lymphoma: Sub‐study of a Phase 2 Geltamo Clinical Trial
2019 · M. Baile, S. Barrena, et al. · Hematological Oncology · 1
Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era
2017 · Antonio Gutierrez, Leyre Bento, et al. · Blood · 1
Real‐world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B‐cell lymphoma: A study from the GELTAMO network
2026 · Mariana Bastos‐Oreiro, Gloria Iacoboni, et al. · HemaSphere
POSTER: ABCL-296 Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study
2025 · Alejandro Bobes, Laura Llorente, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-296: Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study
2025 · Alejandro Bobes, Laura Llorente, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-427 Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study
2024 · Alejandro Bobes, Laura Llorente, et al. · Clinical Lymphoma Myeloma & Leukemia
Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study
2024 · Alejandro Bobes, Laura Llorente, et al. · Clinical Lymphoma Myeloma & Leukemia
Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain
2020 · Pau Abrisqueta Costa, Javier Loscertales, et al. · Blood
Assessment of Bone Marrow Infiltration and Minimal Residual Disease by Multidimensional Flow Cytometry in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
2017 · Mónica Baile, S. Barrena, et al. · Clinical Lymphoma Myeloma & Leukemia
Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project
2015 · Carlos Montalbán, Antonio Díaz-López, et al. · Blood
Works count: 24
Citation count: 193
H-index: 7
I10-index: 4
Year
Topic
Type